CD274 and non-small cell lung carcinoma: Among these studies, Impower 010 was the first one to report primary results in the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, showing a DFS benefit with adjuvant atezolizumab after adjuvant chemotherapy in patients with completely resected stage II-IIIA NSCLC, with pronounced benefit in patients with PD-L1 expression ≥ 1% [46].